Unique ID issued by UMIN | UMIN000015931 |
---|---|
Receipt number | R000018542 |
Scientific Title | Effects of mountain ginseng(Panax ginseng C.A. Meyer) short-term intake, on the improvement for male sexual function and in fatigue. |
Date of disclosure of the study information | 2014/12/12 |
Last modified on | 2015/03/10 11:37:25 |
Effects of mountain ginseng(Panax ginseng C.A. Meyer) short-term intake, on the improvement for male sexual function and in fatigue.
Effects of mountain ginseng(Panax ginseng C.A. Meyer) short-term intake, on the improvement for male sexual function and in fatigue.
Effects of mountain ginseng(Panax ginseng C.A. Meyer) short-term intake, on the improvement for male sexual function and in fatigue.
Effects of mountain ginseng(Panax ginseng C.A. Meyer) short-term intake, on the improvement for male sexual function and in fatigue.
Japan |
Erectile Dysfunction
Medicine in general | Urology |
Others
NO
To investigate the effects of tissue-cultured mountain ginseng (Panax ginseng C.A. Meyer) short-term intake, on male with erectile dysfunction and fatigue.
Efficacy
International Index of Erectile Function and Aging Male Symptoms rating scale.
Interventional
Cross-over
Randomized
Cluster
Double blind -all involved are blinded
Placebo
NO
2
Treatment
Food |
Duration: 7days
Test material: Placebo
4 capsules per day
Duration: 7days
Test material: Mountain ginseng 200mg
4 capsules per day (200mg/day)
20 | years-old | <= |
49 | years-old | >= |
Male
(1) Males between the age of 20 and 49.
(2) Males who have the sexual decline.
(3) Subjects who answered IIEF5(International Index of Erectile Function 5) score more than /equal 21.
(4) Subjects who can make self-judgment and are voluntarily giving written informed consent.
(1) Subjects who are allergic to food related to the test material of this trial.
(2) Subjects who have previous medical history of the serious diseases (heart, liver, kidney, blood, digestive system,metabolism system)
(3) Subjects who are under treatment for hypertension, or who untreated hypertension (not less than level 2).
(4) Subjects who contract or are under treatment for diseases of prostatic.
(5) Subjects who are under treatment for diabetes.
(6) Subjects who are judged as inappropriate for this study by physicians.
20
1st name | |
Middle name | |
Last name | Haruo MARUYAMA |
Universal Clinical Systems Co., Ltd.
Clinical Research Planning Department
4F Komori Build. 2-5-3 Kyobashi Chuo-ku, Tokyo Japan
03-3816-3121
info@uc-system.co.jp
1st name | |
Middle name | |
Last name | MARIKO MOMOI |
Omnica Co.,Ltd
Research team
TN Koishikawa BLDG. 5F, 1-15-17 Koishikawa, Bunkyo-ku, Tokyo, JAPAN
03-5840-9815
momoi@omnica.co.jp
Universal Clinical Systems Co., Ltd.
Omnica Co.,Ltd
Profit organization
NO
2014 | Year | 12 | Month | 12 | Day |
Unpublished
Completed
2014 | Year | 12 | Month | 08 | Day |
2014 | Year | 12 | Month | 15 | Day |
2014 | Year | 12 | Month | 12 | Day |
2015 | Year | 03 | Month | 10 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018542